Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center.

Archivos de la Sociedad Espanola de Oftalmologia Pub Date : 2025-03-07 DOI:10.1016/j.oftale.2025.03.009

P D Lara-Barrera, J L Tovilla-Canales, O Olvera-Morales, E G Castillo-Pérez, Á Nava-Castañeda

{"title":"Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center.","authors":"P D Lara-Barrera, J L Tovilla-Canales, O Olvera-Morales, E G Castillo-Pérez, Á Nava-Castañeda","doi":"10.1016/j.oftale.2025.03.009","DOIUrl":null,"url":null,"abstract":"Background and objective: Blepharospasm is characterized by involuntary, sustained spasms of the orbicularis oculi, corrugator, and procerus muscles. Hemifacial spasm (HFS) is characterized by the involuntary tonic-clonic contraction of the muscles of a hemiface. The main role of botulinum toxin type A (BoNT-A) in the treatment of blepharospasm and HFS is recognized by guidelines around the world. In this study, we evaluated the applicability of botulinum toxin type A in patients with periocular hyperkinetic disorders at the Instituto de Oftalmología Fundación Conde de Valenciana, so that we can share the Mexican experience with the international evidence.Materials and methods: The clinical records of patients diagnosed with facial hyperkinetic disorders treated with botulinum toxin type A (BoNT-A) that were treated from January 2015 to September 2021 were analyzed.Results: A total of 140 records of patients diagnosed with facial hyperkinetic disorder and treated with BoNT-A were analyzed. Facial hyperkinetic disorders that occurred included 5 (3.6%) patients with orbicularis oculi myokymia, 72 (51.4%) with blepharospasm, 62 (44.3%) with hemifacial spasm, and 1 (0.7%) with Meige syndrome. One hundred and twenty patients (85.7%) reported remission of initial symptoms after BoNT-A therapy during the period covered by this study.Conclusions: Botulinum toxin type A is effective and safe as a treatment for facial hyperkinetic disorders in the Mexican population.","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oftale.2025.03.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Blepharospasm is characterized by involuntary, sustained spasms of the orbicularis oculi, corrugator, and procerus muscles. Hemifacial spasm (HFS) is characterized by the involuntary tonic-clonic contraction of the muscles of a hemiface. The main role of botulinum toxin type A (BoNT-A) in the treatment of blepharospasm and HFS is recognized by guidelines around the world. In this study, we evaluated the applicability of botulinum toxin type A in patients with periocular hyperkinetic disorders at the Instituto de Oftalmología Fundación Conde de Valenciana, so that we can share the Mexican experience with the international evidence.

Materials and methods: The clinical records of patients diagnosed with facial hyperkinetic disorders treated with botulinum toxin type A (BoNT-A) that were treated from January 2015 to September 2021 were analyzed.

Results: A total of 140 records of patients diagnosed with facial hyperkinetic disorder and treated with BoNT-A were analyzed. Facial hyperkinetic disorders that occurred included 5 (3.6%) patients with orbicularis oculi myokymia, 72 (51.4%) with blepharospasm, 62 (44.3%) with hemifacial spasm, and 1 (0.7%) with Meige syndrome. One hundred and twenty patients (85.7%) reported remission of initial symptoms after BoNT-A therapy during the period covered by this study.

Conclusions: Botulinum toxin type A is effective and safe as a treatment for facial hyperkinetic disorders in the Mexican population.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos de la Sociedad Espanola de Oftalmologia

自引率

0.00%

发文量